Opinion|Videos|May 19, 2025
The current treatment landscape of mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Explore the latest advancements in metastatic hormone-sensitive prostate cancer treatment, highlighting effective agents and clinical trial outcomes.
Advertisement
Episodes in this series
Treatment Options for mHSPC
Key Themes:
- Current 2025 guidelines recommend ADT with intensification.
- Multiple intensification options include abiraterone, darolutamide, and docetaxel.
- Key clinical trials include ARANOTE, ARASENS, and TITAN.
- All studies demonstrate survival benefit and delayed disease progression with intensification.
Key Points for Physicians:
- ADT monotherapy is no longer the standard of care.
- Multiple evidence-based intensification options exist.
- Selection can be tailored based on patient characteristics and preferences.
- All intensification approaches demonstrate benefit over ADT alone.
Notable Insights: The evolution to combination therapy approaches represents a significant paradigm shift in the management of mHSPC, with multiple effective options now available.
Clinical Significance: The established benefit of intensification therapy has fundamentally changed the treatment landscape for mHSPC, providing multiple evidence-based approaches to improve outcomes.
Advertisement
Related to this article
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5